Cutting-edge
vaccine
development

EXECUTIVE SUMMARY

INTRODUCING
ROCKETVAX

Developing next-generation vaccines leveraging its live-attenuated virus technology.

Mission: To develop the next-generation vaccines for established and new indications and address unmet medical need in the treatment and prevention of infectious diseases.

Lead candidates, live attenuated SARS-CoV-2 COVID-19 vaccines RVX-sCPD9 and RVX-OTS: Target underserved market of next-generation COVID-19 vaccine, aiming to manage current and emergent immune-evasive variants and prevent future pandemic through painless needle-free nasal delivery.

20+

Novel variants
in 2024

#1

Excellent Safety
Profile in animal
studies*

3x

Higher efficacy
in animal studies*

$79b

Addressable
Market

* G. Nouailles et al., Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters. Nature Microbiology, 2023, DOI: 10.1038/s41564-023-01352-8. J. Trimpert et al,. Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. Cell Reports, 2021, DOI:10.1016/j.celrep.2021.109493

THE PROBLEM

THE CHANGING
GLOBAL THREAT
OF COVID-19

2024 FIGURES1

44K

COVID-19 Deaths
in the US

7.7

Peak
hospitalization
(per 100,000)1

Majority of COVID-19 cases
every year
are caused by new
variants1

1. About COVID-19 | COVID-19 | CDC

In 2024, COVID-19 remained a public health threat as the virus continued to mutate causing periodic surges, with majority of new diagnoses caused by novel variants that cannot be effectively mitigated by currently available vaccines.

Although the impact of COVID-19 is no longer as visible as during the peak lockdown period, there is no doubt COVID-19 is here to stay.

CURRENTLY AVAILABLE VACCINE OPTIONS
ALL FALL SHORT

DECLINING

EFFICACY

Efficacy wanes over time, with an estimated 2x drop in effective protection from infection and death after 22 weeks.

Figures adapted from: pmc.ncbi.nlm.nih.gov/articles/PMC11197991

DELIVERY

LIMITATIONS

Currently approved vaccines are mainly injectable, which is inconvenient. In addition, specific storage requirements result in several supply chain limitations.

THE SOLUTION

Rocketvax AG develops next-generation live-attenuated virus vaccines, including a novel nasal vaccine candidate for SARS-CoV-2.

The lead candidates RVX-sCPD9 and RVX-OTS have demonstrated excellent results in animal studies, showcasing tremendous promise to offer superior patient outcomes for both existing and emerging SARS-CoV-2 variants.

LONG-TERM
IMMUNITY

DIFFERENTIATED
TECHNOLOGY

EFFECTIVE
BOOSTER

HIGHLY
SCALABLE

NEEDLE-FREE
DELIVERY

BROAD
EFFICACY

ESTABLISHED
SUPPLY CHAIN

EXCELLENT
TOLERABILITY

STABLE
FORMULATION

All data is preclinical
Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. Cell Reports, 2021, DOI: 10.1016/j.celrep.2021.109493
Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters. Nature Microbiology, 2023, DOI: 10.1038/s41564-023-01352-8
A non-transmissible live attenuated SARS-CoV-2 vaccine. Molecular Therapy, 2023, DOI: 10.1016/j.ymthe.2023.05.004
An Intranasal Live-attenuated SARS-CoV-2 Vaccine Limits Virus Transmission. Nature Communications, 2024, DOI: 10.1038/s41467-024-45348-2
Schon, J., Barut, G. T. et al. A safe, effective and adaptable live-attenuated SARS-CoV-2 vaccine to reduce disease and transmission using one-to-stop genome modifications.
Nature Microbiology, July 2024, DOI: https://doi.org/10.1038/s41564-024-01755-1

All data is preclinical
Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. Cell Reports, 2021, DOI: 10.1016/j.celrep.2021.109493
Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters. Nature Microbiology, 2023, DOI: 10.1038/s41564-023-01352-8
A non-transmissible live attenuated SARS-CoV-2 vaccine. Molecular Therapy, 2023, DOI: 10.1016/j.ymthe.2023.05.004
An Intranasal Live-attenuated SARS-CoV-2 Vaccine Limits Virus Transmission. Nature Communications, 2024, DOI: 10.1038/s41467-024-45348-2
Schon, J., Barut, G. T. et al. A safe, effective and adaptable live-attenuated SARS-CoV-2 vaccine to reduce disease and transmission using one-to-stop genome modifications.
Nature Microbiology, July 2024, DOI: https://doi.org/10.1038/s41564-024-01755-1

REVOLUTIONARY BENEFITS
OF INTRANASAL DELIVERY

NASAL
CAVITY
1

Long-term multifaceted immunity against current and future SARS-CoV-2 variants1

2

Local immunity at the site of virus entry (upper respiratory tissues)2

3

Reduction of both virus infection and transmission3

4

Potential to curb any future COVID-19 pandemic

5

Ease of administration

All Preclinical Data:
1. G. Nouailles et al., Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters. Nature Microbiology, 2023, DOI: 10.1038/s41564-023-01352-8
2. J. Trimpert et al,. Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. Cell Reports, 2021, DOI: 10.1016/j.celrep.2021.109493).
3. Adler JM, et al. (2023). Schon, J., Barut, G. T. et al. A safe, effective and adaptable live-attenuated SARS-CoV-2 vaccine to reduce disease and transmission using one-to-stop genome modifications. Nature Microbiology, July 2024, DOI: https://doi.org/10.1038/s41564-024-01755-1

SUPERIOR INNOVATION AND PRODUCT-MARKET FIT
EVIDENCED BY US GOVERNMENT BACKING

SUPERIOR INNOVATION AND PRODUCT-MARKET FIT
EVIDENCED BY US GOVERNMENT BACKING

Under the US government Project NextGen, Rocketvax AG has signed a letter of intent with the Division of Microbiology and Infectious Diseases (DMID) and the National Institute of Allergy and Infectious Diseases (NIAID) outlining the intended collaboration between the parties for conduct* and sponsoring of a clinical trial investigating Rocketvax AG's RVX-sCPD9 candidate.

Project NextGen is a $5bn public initiative aimed at accelerating and streamlining the rapid development of the next generation of vaccines and treatments through public-private collaborations.

*Clinical Trial Agreement to be signed prior to commencement of clinical trial to develop sCPD9 vaccine, nasal COVID-19 vaccine of Rocketvax AG.

Download Our
Company Presentation

your name

your email

organization name